News

A New Chapter for TOGA: Welcoming Our New Board

Celebrating TOGA’s leadership transition: We honour the service of our past Board members and welcome the new Chair and Directors who will chart TOGA’s future.

As an organisation, TOGA thrives on the commitment and expertise of our leadership. We are pleased to announce some significant changes to our Board, marking the beginning of an exciting new chapter while extending our deepest gratitude to those who have recently concluded their service.

Honouring Our Outgoing Board Members: Thank You for Your Service

We would like to express our thanks and acknowledge the immense contributions of the members who have stepped down from the Board. Their dedication has been invaluable to TOGA’s mission.

A special thank you goes to:

  • Phillip Antippa, for his leadership as Philanthropy Chair.
  • Evan Dukas, for his  guidance as the Governance Chair.

  • Lillian Leigh, for her dedicated service and commitment as Consumer and Advocacy Chair.

Their service has left a lasting, positive impact on the organisation, and we wish them the very best in their future endeavours!

Welcoming Our New Board: Charting TOGA’s Future

We are thrilled to introduce the appointed office bearers of the new TOGA Board, who bring a wealth of experience, insight, and passion to their roles. We are confident in their ability to lead TOGA forward and strengthen our commitment to our community.

We congratulate the following members on their new or continued appointments:

  • Prof Emily Stone will be taking on the top leadership role as our new Chair. Prof Stone brings continuity and vision, previously serving effectively as the Deputy Chair and Company Secretary.

  • Prof Nick Pavlakis will be stepping down from the Chair role. We are delighted that Prof Pavlakis will remain on the Board to provide crucial support to Prof Stone during this transition phase. His continued guidance will be a major asset.

  • A/Prof Mel Moore will be taking on the position of Deputy Chair. A/Prof Moore will also retain the Education portfolio, ensuring our commitment to knowledge and development remains strong.

  • Prof Ben Solomon has been appointed as our new Company Secretary. Prof Solomon will continue his excellent work by retaining the Scientific portfolio.

  • Prof Shalini Vinod will be the Finance Chair. Previously, Prof Vinod was the Communications and Grants Chair, but the Board has decided that in its next stage of growth, this is the remit of TOGA Operations staff.
  • Ms Catherine Sim has been reappointed to the Board, bringing financial and legal expertise. We thank her for her dedication to TOGA’s processes and longevity. 
  • We extend a warm welcome to Dr Tracy Leong, who is new to the Board. We look forward to the fresh perspectives and expertise she will bring to our governance.

This blend of experienced and new voices will ensure a smooth transition and dynamic leadership for TOGA. We look forward to the progress and achievements that this new Board will bring in the coming term.

Please join us in thanking the outgoing members and welcoming the new TOGA Board!

Stay tuned to the TOGA website for updates on our new strategic initiatives and upcoming events!

Share this

Facebook
Twitter
LinkedIn
Consumer involvement can strengthen research design and grant applications. This practical guide explains when to involve consumers, what to ask, how to document their influence
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.